AnaptysBio Inc (NASDAQ:ANAB) was the target of a significant increase in short interest during the month of December. As of December 29th, there was short interest totalling 1,387,012 shares, an increase of 40.3% from the December 15th total of 988,390 shares. Based on an average daily volume of 280,607 shares, the short-interest ratio is presently 4.9 days. Currently, 9.8% of the company’s shares are sold short.
Several large investors have recently modified their holdings of the company. Perceptive Advisors LLC increased its position in shares of AnaptysBio by 3.2% during the third quarter. Perceptive Advisors LLC now owns 982,269 shares of the biotechnology company’s stock worth $34,330,000 after acquiring an additional 30,000 shares during the period. Citadel Advisors LLC purchased a new position in shares of AnaptysBio during the third quarter worth approximately $20,406,000. Artal Group S.A. increased its position in shares of AnaptysBio by 459.4% during the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after acquiring an additional 205,310 shares during the period. Vanguard Group Inc. increased its position in shares of AnaptysBio by 22.6% during the second quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock worth $4,931,000 after acquiring an additional 37,932 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in AnaptysBio by 210.2% during the third quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock valued at $6,363,000 after buying an additional 124,219 shares during the period. 75.48% of the stock is currently owned by institutional investors and hedge funds.
AnaptysBio (NASDAQ ANAB) opened at $110.45 on Friday. The company has a market cap of $2,570.00 and a P/E ratio of -73.15. AnaptysBio has a 1 year low of $15.17 and a 1 year high of $116.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77.
Several brokerages have issued reports on ANAB. Wedbush reissued a “positive” rating and issued a $82.00 price objective (up previously from $75.00) on shares of AnaptysBio in a research note on Tuesday, November 7th. Robert W. Baird set a $69.00 price objective on shares of AnaptysBio and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Stifel Nicolaus reissued a “buy” rating and issued a $76.00 price objective (up previously from $35.00) on shares of AnaptysBio in a research note on Friday, October 13th. Credit Suisse Group raised their price objective on shares of AnaptysBio from $38.00 to $85.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 10th. Finally, Zacks Investment Research downgraded shares of AnaptysBio from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $88.00.
COPYRIGHT VIOLATION NOTICE: “AnaptysBio Inc (ANAB) Sees Significant Increase in Short Interest” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://weekherald.com/2018/01/19/anaptysbio-inc-anab-sees-significant-increase-in-short-interest.html.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.